A carregar...
Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
Lung cancer mortality has decreased over the past decade and can be partly attributed to advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have rapidly evolved from investigational drugs to standard of care for the treatment of metastatic non‐small cell lung cancer...
Na minha lista:
| Publicado no: | Cancer Commun (Lond) |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8045926/ https://ncbi.nlm.nih.gov/pubmed/33689225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cac2.12153 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|